Evidence map›Paper›PMID 41081987›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

Performance of CHROMAgar™ LIN-R screening medium for the detection of linezolid-resistant enterococci in Croatian tertiary care hospital.

Mislav Peras, Jennifer Karin Bender, Guido Werner, Lucija Brechelmacher, Tomislav Kuliš, Ivana Mareković

Abstract readMulticenter StudyEvaluation Study
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mislav PerasInstitute of Public Health Zagreb County, Zaprešić, Croatia.
Jennifer Karin BenderRobert Koch Institute, Wernigerode, Germany.
Guido WernerRobert Koch Institute, Wernigerode, Germany.
Lucija BrechelmacherClinical Department of Clinical Microbiology, Infection Prevention and Control, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb, 10 000, Croatia.
Tomislav KulišClinical Department of Clinical Microbiology, Infection Prevention and Control, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb, 10 000, Croatia.
Ivana MarekovićClinical Department of Clinical Microbiology, Infection Prevention and Control, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb, 10 000, Croatia. imarekov@kbc-zagreb.hr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe evaluated the performance of CHROMAgar™LIN-R agar plates as part of a multicenter study ("APPLE").

methodsThe study was performed using 1200 rectal swabs and stool samples.

resultsWe identified 168 enterococci with 75.6% (127/168) confirmed as linezolid-resistant (LRE) by the disc diffusion method. Among these, 48 LRE were single-patient isolates, of which 75% (36/48) showed resistance to vancomycin and 4.2% (2/48) to vancomycin and tigecycline. Overall LRE prevalence was 4.3% (48/1113) with the highest prevalence at adult hematology wards (11.3%). False-positivity rate was 24.4% (41/168) and significantly lower in neurological intensive care and hematology departments compared to pediatric hematology (adjusted p = 0.0034 and p = 0.0014, respectively). Prevalence was significantly higher in stool samples (8.8% vs. 1.6%) (p < 0.0001).

conclusionAssessing the performance of CHROMAgar™LIN-R among different patient groups and sample types may enhance its application.

Indexed as

Anti-Bacterial AgentsCulture MediaDrug Resistance, BacterialEnterococcusGram-Positive Bacterial InfectionsLinezolidAdolescentAdultAgedChildChild, PreschoolCroatiaFecesFemaleHumansMaleAnti-Bacterial AgentsCulture MediaLinezolidAntimicrobial resistanceChromogenic mediaInfection controlSurveillance culture

Identifiers

PMID41081987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.